{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:22:23Z","timestamp":1783786943314,"version":"3.55.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,22]]},"abstract":"<jats:p>Chemotherapy for patients with recurrent cancer aims to obtain survival benefits, relieve symptoms, and improve quality of life. We used oral cyclophosphamide and bevacizumab (BEV) combination therapy in recurrent ovarian and peritoneal cancer cases, where standard chemotherapy was infeasible. Subsequently, we evaluated the safety and efficacy of this treatment. Between August 2014 and June 2020, patients received the following regimen: oral cyclophosphamide 50\u2009mg daily and intravenous cyclic BEV 15\u2009mg\/kg every 3 weeks. Data from 2 facilities were retrospectively analyzed. Twenty-two patients were enrolled (20 with ovarian cancer and two with peritoneal cancer). The median follow-up period and age were 18.9 months (range, 5.0\u201351.5) and 60 years (range 37\u201381), respectively. Sixteen patients had platinum resistance. The median number of previous chemotherapy regimens was 2.5 (range 0\u20135). The median implementation cycle was five (range 2\u201314). Eighteen patients discontinued treatment due to side effects (3 patient) and disease progression (15 patient). Grade 2 toxicities included neutropenia (1 patient), proteinuria (1 patient), hypertension (2 patient), and esophagitis (1 patient). Two patients had complete response and one had a partial response. Five patients had stable disease. The response rate in platinum-sensitive recurrence was 33.3%, and 7.1% in platinum-resistant recurrence, and a clinical benefit was found in 8 (36.3%) patients. The median PFS and overall survival from cyclophosphamide and BEV initiation was 5.3 months (range, 0.8\u201323.5) and 9.2 months (range, 4.8\u201351.5), respectively. The combination of oral cyclophosphamide and BEV does not have a high response rate, but is well-tolerated and can be used safely in patients who are difficult to treat after second-line chemotherapy.<\/jats:p>\n          <jats:p>Data from 2 facilities were retrospectively analyzed.<\/jats:p>","DOI":"10.1097\/md.0000000000032880","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T12:04:13Z","timestamp":1677240253000},"page":"e32880","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Combination therapy of oral cyclophosphamide and bevacizumab for patients with recurrent ovarian and peritoneal cancer"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-9772","authenticated-orcid":false,"given":"Mayako","family":"Goto","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kansai Rousai Hospital, Amagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsubamoto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roze","family":"Isono-Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Takimoto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Tashima","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kansai Rousai Hospital, Amagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kansai Rousai Hospital, Amagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kansai Rousai Hospital, Amagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250805","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary.","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study.","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"R3-20250805","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"R4-20250805","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer.","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-20250805","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 trial of bevacizumab in ovarian cancer.","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20250805","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"R7-20250805","doi-asserted-by":"crossref","first-page":"LBA5002","DOI":"10.1200\/jco.2012.30.18_suppl.lba5002","article-title":"Aurelia: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).","volume":"30","author":"Pujade-Lauraine","year":"2012","journal-title":"J Clin Oncol"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2007.07.017","article-title":"Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.","volume":"107","author":"Chura","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R9-20250805","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital.","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-20250805","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s12094-008-0287-5","article-title":"Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.","volume":"10","author":"Jurado","year":"2008","journal-title":"Clin Transl Oncol"},{"key":"R11-20250805","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000320602","article-title":"Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.","volume":"79","author":"S\u00e1nchez-Mu\u00f1oz","year":"2010","journal-title":"Oncology (Huntingt)"},{"key":"R12-20250805","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2012.04.003","article-title":"Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.","volume":"126","author":"Matulonis","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R13-20250805","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3802\/jgo.2013.24.3.258","article-title":"The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer.","volume":"24","author":"Barber","year":"2013","journal-title":"J Gynecol Oncol"},{"key":"R14-20250805","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R15-20250805","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FASL establishes a selective immune barrier promoting tolerance in tumors.","volume":"20","author":"Motz","year":"2014","journal-title":"Nat Med"},{"key":"R16-20250805","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R17-20250805","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/ijc.28259","article-title":"Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.","volume":"133","author":"Vives","year":"2013","journal-title":"Int J Cancer"},{"key":"R18-20250805","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+regulatory T cell and restores T and NK effector function in end stage cancer patients.","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"R19-20250805","doi-asserted-by":"crossref","first-page":"e0173693","DOI":"10.1371\/journal.pone.0173693","article-title":"The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: a meta-analysis.","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"key":"R20-20250805","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression.","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"R21-20250805","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial.","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"key":"R22-20250805","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:11:55Z","timestamp":1754424715000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032880","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,22]]}}}